Patents and know-how for individualized dosing, by clinicians and AI.

Dose decisions are the next step for AI in care.

New therapies work only as well as each dose is managed over time: the right starting dose, careful titration, keeping each patient within their therapeutic window, and managing side effects.

More than a billion people live with obesity, and GLP-1 therapy has brought millions into treatment. Among people taking it for weight loss without diabetes, about two in three stop within a year, and side effects make stopping more likely.

In chronic care, fulfillment and monitoring have moved to software. Dose changes are next. Today software proposes a dose change and a clinician approves it; next, software makes routine changes within limits a clinician has set, and clinicians handle the exceptions. AI agents will speed this up: they can review every patient's readings and side effects every day, at a scale no clinic could staff. What they need is dose rules that are individual to each patient and explicit enough for a clinician or a regulator to inspect.

Granted claims on the dose decisions care is now automating.

Our core patents claim the dosing method itself: how a patient's starting dose is chosen, and how it is adjusted from their own data, such as weight, blood pressure readings and reported side effects. Because the claims set out the method rather than the tool, a partner can run the same approach with clinicians today and in software as its care automates.

Our patents and applications cover:

Further applications are pending in the United States, Europe and Japan. The patents are held by Morchella Medical Limited, and the assignments are recorded at the US Patent and Trademark Office.

AI that changes treatment will need to show its working.

Regulatory frameworks for clinically acting software are being written now. The drafts published so far point to the same demands: systems that stay within limits, record what they did, and can show why.

Our dosing rules are written to meet those demands. They are deterministic and documented, and they state when software may change a dose and when it must hand over to a clinician. Our applications extend the estate to the safeguards around dosing software.

Patents, dosing rules and evidence to build AI-run dosing on.

• PatentsA protected position to bring personalized and automated dosing to market, under granted method-of-treatment claims, licensed by drug, field and territory.
• Dosing rules and modelsPharmacokinetic, pharmacodynamic and machine-learning models, and dosing rules ready to run in software and open to inspection by a clinician or regulator, so a partner does not build them from scratch.
• Clinical evidence and know-howOur remote titration trial with Queen Mary University of London, published in the Journal of the American Heart Association in 2024, enrolled 205 patients who reported blood pressure and side effects from home while their dose was adjusted.

We license and partner.

We work with pharmaceutical and biotech developers, telehealth and direct-to-patient platforms, and providers of clinical software. We do not build products that compete with theirs.

Morchella Medical was formed in 2026 by the team that developed this work.